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SUMMARY
For over ﬁfty years, human African trypanosomiasis (HAT, sleeping sickness) has been treated with suramin, pentamidine
and the very toxic organo-arsenical melarsoprol that was the only drug available for eﬀective treatment of the second stage
of the disease. Recently there have been signiﬁcant eﬀorts using molecular and biochemical approaches to drug design,
including high-throughput screening, but the number of lead compounds with promising activity againstT. brucei spp. and
an acceptable toxicity index has remained astonishingly small. Clinical research continues to be diﬃcult due to the economic
constraints and the complexity of trials on a low prevalence disease in remote and impoverished African regions. Despite
those limitations the situation for the patients is improving thanks to the combination of a number of critical factors. By the
late 1990s the disease had reached epidemic levels that triggered political support. WHO would sign a donation agreement
with the manufacturers for all drugs to treat HAT. A result of this agreement was that eﬂornithine which is much safer than
melarsoprol became available and widely used by non-governmental organizations. The IMPAMEL I and II programmes
demonstrated that against all odds the conduct of clinical trials on HAT was feasible. This allowed the initiation of trials
on combination therapies which eventually resulted in the nifurtimox-eﬂornithine combination treatment (NECT). This
combination is currently being introduced as ﬁrst line treatment, and there is even the prospect of having a new compound,
fexinidazole, in the development pipeline. This review summarizes the key information about the existing drugs and gives a
comprehensive summary about the recent and currently ongoing eﬀorts towards new drugs.
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INTRODUCTION
The options for treatment of sleeping sickness are
very limited and the selection of the appropriate drug
for treatment is determined primarily by the disease
stage and the causative pathogen, but in developing
countries is also dependent on the logistics and tech-
nical level of the treatment facility. Presently, all
drugs for treatment of human African trypanoso-
miasis (HAT) are donated to theWHO by the manu-
facturers sanoﬁ-aventis and Bayer in the framework
of a three-point agreement of adequate medicine
supplies, disease surveillance and management, plus
research and development for new treatments (Bayer,
2002; IFPMA and International Federation of Phar-
maceutical Manufacturers and Associations, 2008).
The drugs can be ordered by authorized national
programmes or NGOs at the cost of shipment.
An encouraging result of the agreement is that
eﬂornithine, which is much safer than melarsoprol,
is again available and has become widely used by
non-governmental organizations (Chappuis, 2007)
and increasingly also by national control pro-
grammes. Nevertheless, well tolerated and simple to
usemedicines to treat the disease are needed. Theway
towards this goal has been a narrow and bumpy track
in the past, but there are clear signs for a signiﬁcant
improvement. This review summarizes the key facts
about the existing drugs and gives a comprehensive
summary of the recent and currently ongoing eﬀorts
towards new drugs.
PENTAMIDINE
Pentamidine, currently available as pentamidine
isethionate, Pentacarinat® (sanoﬁ-aventis) in 200mg
vials for intramuscular injection, is the drug of
choice for treatment of ﬁrst stage HAT caused by
T. b. gambiense. The standard dosage regimen is
4 mg kg−1 body weight per day for seven days.
Because of the risk of hypotension after intravenous
(i.v.) application the drug is usually given as deep
intramuscular (i.m.) injection. In settings where good
nursing care and monitoring are available, an intra-
venous infusion in saline over two hours may be used
as an alternative. The recommended dose calculation
for pentamidine has shifted over time from the base
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to the salt moiety resulting in a signiﬁcant reduction
of the active molecule injected when Pentacarinat® is
given compared to the formerly used Lomidine®
(Dorlo and Kager, 2008). Whereas this reduction
seems to have an eﬀect on the treatment eﬃcacy of
cutaneous leishmaniasis, the eﬃcacy of pentamidine
in HAT continues to be excellent and no change of
the current practice, but rather a formal adaptation of
the recommendation seems appropriate. The stable
very low relapse rate, despite the extensive former
use in prophylaxis programmes (Waddy, 1970),
may be due to the uptake of the molecule by three
diﬀerent transporters (Barrett et al. 2007). Pharma-
cokinetic evidence indicates that three injections may
be equally eﬀective (Bronner et al. 1991; Bronner,
1994) and a respective comparative clinical trial is cur-
rently ongoing to evaluate this (ISRCTN55042030).
Due to the high potency of pentamidine and the low
drug levels detected in the CSF (Bronner et al. 1991)
the use to treat ‘intermediate stage’ patients (up to 10
or 20 white blood cells (WBC) mm−3 in CSF) was
suggested (Doua et al. 1996). The resulting eﬃcacy
in respective studies is equivocal (Ruiz et al. 2002;
Lejon et al. 2003; Balasegaram et al. 2006b). Hence
the use of pentamidine for patients with 5–20
cells mm−3 should not be generally recommended,
but should be restricted to areas where melarsoprol is
still in use, and where a very good adherence to follow
up and rapid access to rescue treatment is guaranteed.
Compared to the drugs used for treatment of
second stage HAT, pentamidine is well tolerated and
most reactions are reversible. In the treatment of
HAT by i.m. injection, site pain and transient swell-
ing, abdominal pain, diarrhoea, nausea, vomiting and
hypoglycaemia (5–40%) are the most frequently re-
ported adverse events (Médecins Sans Frontières,
2007). Other important adverse drug reactions
(ADRs) like leucopenia, thrombocytopenia, hyper-
potassaemia and QT-prolongation which are seen in
treatment of other diseases e.g. Pneumocystis carinii
(Anonymous, 2008), are only rarely reported in HAT
probably due to the lack of adequate tools for patient
monitoring. In addition, hyperglycaemia was re-
ported (5%), very rarely with persistent manifestation
of diabetes (Doua and Yapo, 1993).
SURAMIN
Suramin, introduced in 1920, is the oldest trypano-
cidal medicine and one of the oldest drugs still in use
along with quinine and aspirin, for instance. It is
marketed as Germanin® (Bayer) in ampoules of 1 g
and is eﬀective against the ﬁrst stage of both forms
of the disease. For treatment of T. b. gambiense
pentamidine is generally preferred today because of a
claimed higher eﬃcacy and because suramin is also
highly active against Onchocerca spp. with the risk of
strong allergic reactions in areas where this parasite is
present.
The most commonly used dosage regimen consists
of a test dose of 4–5mg kg−1 body weight at day 1,
followed by ﬁve injections of 20mg kg−1 bodyweight
i.v. every 3–7 days (e.g. days 3, 5, 12, 19, 26) of
suramin (WHO, 1986) with a maximum dose per
injection of 1 g. The compound deteriorates rapidly
in air and should be injected immediately after dilu-
tion in distilled water (Gustafsson et al. 1987). No
new research on a more concise treatment schedule
has been initiated despite a recommendation by the
WHO TDR Scientiﬁc Working Group on African
Trypanosomiasis of 2001.
Some degree of kidney damage is common, but
nephrotoxicity is usually mild and reversible. The
ﬁrst symptoms of renal impairment are albuminuria,
later cylinduria and haematuria. Other adverse drug
reactions reported are early hypersensitivity reactions
occurring in 0·1–0·3% of cases causing nausea, circu-
latory collapse and urticaria, and rare late hypersen-
sitivity reactions such as exfoliative dermatitis and
haemolytic anaemia, peripheral neuropathy, and
bonemarrow toxicitywith agranulocytosis, thrombo-
cytopenia (Burri and Brun, 2008).
Suramin has one of the longest half-lives of all
drugs applied to humans; depending on the dosage
schedule half-lives of 44–92 days were reported.
99·7% of the drug is bound to plasma proteins, which
places suramin in the class of the most extensively
bound drugs (Burri et al. 2004). Several diﬀerent
proteins have been reported to be involved (e.g.
albumin, globulins, ﬁbrinogen). Such an extensive
binding intrinsically bears the risk of adverse reac-
tions through displacement from its binding by inter-
acting drugs.
It is not known if suramin resistant T. b. gambiense
or T. b. rhodesiense strains exist today. Observed re-
lapses could be attributed to incorrectly diagnosed
2nd stage infections.
MELARSOPROL
The organo-arsenic compound melarsoprol,
Arsobal® (sanoﬁ-aventis) has until very recently been
the most widely used drug for treatment of second
stage HAT caused by T. b. gambiense in resource-
limited countries. For this form of the disease,
melarsoprol will become progressively replaced by
the Nifurtimox-Eﬂornithine Combination therapy
(NECT) treatment (see below), but it is still the only
choice for treatment of T. b. rhodesiense HAT. For
T. b. gambiense an abridged treatment schedule of
10 injections (2·2 mg kg−1 bodyweight per day) on
consecutive days was recommended by the Inter-
national Scientiﬁc Council for Trypanosomiasis
Research and Control (ISCTRC) in 2004 (Schmid
et al. 2005). For treatment of T. b. rhodesiense various
lengthy and complicated treatment schedules invol-
ving three series of three injections on consecutive
days, with intervening rest periods of seven days,
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sometimes preceded by single injections of suramin,
are still used (Burri and Brun, 2008). Research to
assess the 10-day schedule in T. b. rhodesiense was
very recently completed (see clinical research and
outlook section below) and the same abridged
treatment schedule of 10 injections (2·2 mg kg−1
bodyweight per day) on consecutive days was
recommended by the 30th ISCTRC 2009 inKampala
(oﬃcial publication pending).
Hospitalization during treatment with melarsoprol
is mandatory because of the high rate of adverse
drug reactions which may be severe or life threat-
ening. The most important one is an encephalopathic
syndrome (ES) which occurs very variably in
an average of 4·7% T. b. gambiense and 8·0%
T. b. rhodesiense patients, with a case fatality rate of
44% and 57% respectively (Seixas, 2004). An immu-
nological basis for ES has long been suspected and
recent investigations indicating that a small number
of alleles of the human leukocyte antigen (HLA) were
associated with a signiﬁcantly increased risk for
ES have corroborated this hypothesis (Seixas, per-
sonal communication). The management of ES
remains very diﬃcult and there is no good scientiﬁc
evidence for the best approach. Currently the use
of dexamethasone, diazepam and where possible
the maintenance of the physiological balance are
recommended (Médecins Sans Frontières, 2007).
The use of mannitol and adrenalin, which was
habitual for a long time, was shown to be associated
with a high mortality in a recently conducted study
(Seixas, unpublished data). Recently, the successful
experimental use of a substance P receptor anta-
gonist, aprepitant (Emend®, MSD) in rats to reduce
the CNS neuroinﬂammatory reaction, was reported
(Rodgers et al. 2007). Other reported severe adverse
reactions are peripheral motoric (palsy) or sensorial
(paresthesia) neuropathies (Van Nieuwenhove,
1999). Recent investigations showed that treatment-
induced ECG alterations were frequent, but clini-
cally irrelevant (Blum et al. 2007). Skin reactions
like pruritus and maculopapular eruptions are
fairly common, but severe complications like bullous
eruptions only occur in less than 1% (WHO, 1998;
Schmid et al. 2005). The irritating and painful eﬀects
of the injections, often leading to thrombophlebitis
can be mitigated by a good injection technique and
the use of new or sharp injection needles.
In several foci of Angola, the Democratic Republic
of the Congo (DRC), Southern Sudan and Uganda,
treatment failures have reached levels of 30% of
those treated. Several parasites isolated from relapse
cases in the ﬁeld lack the P2 transporter which is
necessary to import melarsoprol into the parasite
(summarized in Barrett et al. 2007). However, so far
the demonstration of parasite resistance in the ﬁeld
has been hampered by diﬃculties in retrieving
T. b. gambiense isolates from patients for investi-
gation.
EFLORNITHINE
Eﬂornithine, Ornidyl® (sanoﬁ-aventis), is the only
molecule which has been registered against HAT in
the past 50 years. Several studies comparing melar-
soprol and eﬂornithine showed a clearly reduced
mortality and cumulative incidence of relapses under
eﬂornithine and the drug is therefore recommended
as ﬁrst line treatment for second stage T. b. gambiense
HAT (Chappuis et al. 2005; Balasegaram et al. 2006a;
Checchi et al. 2007), but the use of eﬂornithine
against T. b. rhodesiense is not advised because of the
innately reduced susceptibility of this parasite due to
a higher ornithine decarboxylase turnover (Iten et al.
1997). The most commonly used dosage regimen
for the treatment of T. b. gambiense HAT consists
of 100mg kg–1 body weight at intervals of 6 h for
14 days of eﬂornithine given as short infusions (Burri
and Brun, 2008). An abridged 7-day treatment
regimen can not be generally recommended due to
the signiﬁcantly lower eﬃcacy (Pepin et al. 2000).
Adverse drug reactions during eﬂornithine therapy
are frequent and the characteristics are similar to
other cytotoxic drugs for the treatment of cancer.
Their occurrence and intensity increase with the
duration of treatment and the severity of the general
condition of the patient. Generally, adverse drug
reactions to eﬂornithine are reversible after the end
of treatment. They include convulsions (7%), gastro-
intestinal symptoms like nausea, vomiting and
diarrhoea (10%–39%), and bone marrow toxicity lead-
ing to anaemia, leucopenia and thrombocytopenia
(25–50%). In experimental cancer treatment with
considerably longer therapeutic schedules hearing
impairment (5%) and alopecia (5–10%) were also
reported (Burri and Brun, 2003).
Eﬂornithine is very expensive and only the do-
nation programme has allowed its increasing use in
endemic countries. The introduction of eﬂornithine
as ﬁrst line treatment replacing melarsoprol in treat-
ment facilities operated by national control pro-
grammes is only progressing slowly. This is mainly
due to the complexity of eﬂornithine administration,
requiring 56 short infusions over two weeks and the
associated substantial logistic implications and in-
direct costs (e.g. acquisition and transport of infusion
materials from the control programme base to the
ﬁeld), and the need for suﬃcient and trained human
resources to maintain adequate round-the-clock
nursing care. Since 2007 the WHO, with funding
from the sanoﬁ-aventis programme, has provided
eﬂornithine in kits including all necessary ancillary
materials (Priotto et al. 2008), but considerable
logistic constraints remain as the kit for two patients
has a volume of about 1m3.
An oral formulation was thought to solve many of
the treatment related diﬃculties, but was abandoned
after discouraging results of a pharmacokinetic trial
(Na-Bangchang et al. 2004; Jansson et al. 2008).
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Another serious concern with eﬂornithine mono-
therapy is the probability of the development of resis-
tance, which would have catastrophic consequences.
The ﬁrst reports of a decreasing eﬃcacy of eﬂor-
nithine in certain centres in Southern Sudan seem to
have already emerged (Dr. P. Simarro, WHO,
personal communication). It is thus vital to protect
the eﬃcacy of this drug by using it in combination
regimens as soon as possible.
CLINICAL RESEARCH AND OUTLOOK
Clinical research on new drugs for treating HAT
continues to be limited for various reasons. Follow-
ing economic logic, the interest of commercial cor-
porations in the development of new drugs against
this disease only aﬀecting extremely poor populations
is limited. Despite largely increased molecular, bio-
chemical and screening eﬀorts, the number of lead
compounds with promising activity against T. brucei
spp. and an acceptable toxicity index has remained
astonishingly small. Last but not least, clinical trials
to assess the safety and the eﬃcacy of new drugs are
extremely diﬃcult to conduct due to the low preva-
lence, the remoteness of the patients and the very long
follow up time. Hence, the currently available
options for the treatment are suboptimal for lack of
eﬃcacy and toxicity, and resistance is a latent threat
due to the exclusive use of monotherapies. For those
reasons, recent eﬀorts have focused on optimizing the
therapeutic regimens and on developing combination
therapy using the registered drugs or those used to
treat related diseases.
IMPAMEL III (Improved Application of Melarsoprol)
The abridged treatment schedule of 10 injections
(2·2mg kg–1 bodyweight per day) of melarsoprol
had been recommended for treatment of second
stage T. b. gambiense HAT by the ISCTRC in 2004
after the completion of the IMPAMEL I and II pro-
grammes. The evaluation of the schedule against
T. b. rhodesiense of the schedule was very recently
completed (IMPAMEL III trials). Due to the very small
total patient number and their remote location,
no pivotal trials are feasible. Therefore, a proof-
of-concept trial (n=60) and a utilization study
(n=78) using historic controls as comparator were
sequentially carried out. The incidence of encephalo-
pathic syndromes in the trial population was 11·2%
(CI 5–17%) versus 13% (CI 9–17%) in the historic
data. The respective case fatality rates were 8·4%
(CI 3–13·8%) and 9·3% (CI 6–12·6%). All patients
discharged alive were free of parasites at the end
of treatment. Six months after discharge 99% of
patients were considered clinically cured. The total
hospitalization time was reduced from 29 to 13 days
(Kuepfer, 2009). This ﬁrst improvement of the
treatment after 60 years bears considerable socio-
economic advantages, but this cannot hide the fact
that new and adequate drugs are urgently needed to
treat this form of the disease.
NECT
An alternative compound which was considered
in the context of reassessment of existing drugs is
nifurtimox (Lampit®, Bayer), which was introduced
for treatment of Chagas disease (T. cruzi) in the late
1960s. It is not registered to treat African trypano-
somiasis but had been experimentally used with
equivocal outcomes and became recently available for
compassionate treatment in combination with other
trypanocidal drugs of patients not responding to
melarsoprol (Priotto et al. 2006). Diﬀerent empiri-
cally derived treatment schedules were used; for
combination with other trypanocidal drugs usually
15mg kg–1 per day for 10 days by oral route was
selected. Nifurtimox is generally not well tolerated,
and only about one-third of the patients remain free
from adverse drug reactions but generally adverse
eﬀects are not severe, very rarely fatal, and are dose
related. Gastrointestinal disturbances with nausea,
abdominal pains and vomiting are very frequent, and
neurological adverse reactions with general convul-
sions, tremor or agitation may occur. The develop-
ment of peripheral polyneuropathy and generalized
skin reactions were seen as occasional events (Burri
and Brun, 2008). The frequency of adverse reactions
increases with therapy duration and all were rapidly
reversible after discontinuation of the drug (Pepin
et al. 1992).
Several trials assessing combinations of eﬂor-
nithine, melarsoprol and nifurtimox have been con-
ducted. In all trials, the eﬃcacy was better in the
combination arms compared to the monotherapies.
However, combinations containing melarsoprol re-
sulted in very high frequencies of severe adverse drug
reactions (Priotto et al. 2006; Bisser et al. 2007).
Eventually, amulti-centre trial, NECT – nifurtimox-
eﬂornithine combination therapy, was initiated in
the Republic of Congo and the DRC comparing
NECT with the standard eﬂornithine therapy
(Chappuis, 2007). The treatment consisted of eﬂor-
nithine 200mg kg−1 i.v. short infusion every 12 h for
7 days plus nifurtimox 15mg kg−1 orally per day
(5 mg kg−1 every 8 h) for 10 days. This represents a
considerable simpliﬁcation compared to the standard
eﬂornithine schedule: The number of infusions can
be reduced from 56 to 14, it shortens hospitalization
time by one third and reduces the total amount of
eﬂornithine by half (Priotto et al. 2007). The in-
ventors took a substantial risk in the dose deter-
mination, because eﬂornithine has a very short
half-life requiring four daily drug applications and
because a seven days short-course eﬂornithine
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treatment previously led to signiﬁcantly lower
eﬃcacy (Pepin et al. 2000). It was argued that the
short half-life of eﬂornithine might be balanced
by the long-lasting pharmacodynamic eﬀect on
trypanosomes, explained by the long time (18–19 h)
needed by T. b. gambiense to replenish their orni-
thine decarboxylase after inhibition by eﬂornithine
(Priotto et al. 2007) and that a previous combination
trial using standard dose eﬂornithine with nifurtimox
had resulted in very low relapse rate (Priotto et al.
2006). A total of 286 patients were enrolled, the
relapse rate after 18 months of follow up was 5·7%
under eﬂornithine and 1·4% under NECT treatment
(intention to treat population, i.e. all randomised
patients, apart from one who absconded on day 1).
Adverse events were frequent in both groups;
41 (28·7%) patients in the eﬂornithine group and
20 (14·0%) in the NECT group had major (grade 3
or 4) reactions (Priotto et al. 2009). A smaller scale
trial with a similar design was conducted in two
treatment centres in Uganda (ISRCTN03148609).
Only very generic data have been made available
so far, but these support a positive evaluation of
the NECT treatment (Kansiime et al. 2009). NECT
has large advantages over the eﬂornithine mono-
therapy as it is easier to administer, reduces the
necessary drug, staﬀ and logistic resources, requires
a signiﬁcantly shorter hospital stay and it may be
predicted to have a positive eﬀect against develop-
ment of drug resistance. Those features are of
particular importance considering the rural character
of the treatment centres. Based on the favourable
results of the trials conducted so far, an application
for the inclusion of nifurtimox, to be used in
combination with eﬂornithine, for treatment of
second stage T. b. gambiense HAT into WHO’s
Essential Medicines List (EML) was submitted by
the Drugs for Neglected Diseases Initiative (DNDi)
and was granted inMay 2009 (DNDi, 2009). A study
evaluating the tolerability, feasibility, and eﬀective-
ness of NECT in ‘real-life’ conditions was initiated
simultaneously (NECT-FIELD) (DNDi, 2008a)
and within one year the planned 620 patients had
been enrolled in the DRC (C. Schmid, personal
communication). By March 2010, NECT had been
introduced inCentral African Republic, Chad,DRC,
Equatorial Guinea, Sudan and Uganda (DNDi,
2010).
This momentum should now be used to
submit the NECT schedule to studies in the
T. b. rhodesiense vervet monkey model. Using a
futility approach, a decision whether in-depth studies
in human are justiﬁed or not could be relatively
rapidly made. Based on the pharmacology of the
drugs (see above) the likelihood for success with
T. b. rhodesiense is limited, but as this will be the
only potential new approach to treat this form of
the diseases for a long time, the eﬀort would be
justiﬁed.
DB289
The development of new medicines against HAT
has recently experienced a serious setback, when the
only new drug in clinical assessment failed at the very
end of the development programme. The inter-
national Consortium for Parasitic Drug Develop-
ment (CPDD) led by the University of North
Carolina, Chapel Hill, USA, received funding by
the Bill and Melinda Gates Foundation (BMGF) to
discover and bring selected molecules to registration.
DB289 (pafuramidine maleate), an orally active pro-
drug had proven considerable trypanocidal activity
and low toxicity in pre-clinical testing andwas chosen
for further development in the year 2000. The com-
pound underwent extensive Phase I (healthy volun-
teers) and Phase II testing (proof of concept in
patients). A pivotal Phase III trial was initiated in
August 2005 and its follow-up ended in mid-2009.
273 patients were enrolled in four centres in the DRC
and in one centre each in Angola and South Sudan.
All patients completed the assigned study drug re-
gimen of pafuramidine 100mg twice a day oral for
10 days or pentamidine 4mg kg–1 i.m. for 7 days.
After unblinding, the safety proﬁle of pafuramidine
appeared to be inconspicuous; ALT and AST eleva-
tions were frequently recorded but only reached
Grades 2 and 3 elevation under pentamidine therapy.
The per protocol eﬃcacy at the 12-months follow up
was 89% for pafuramidine and 96% for pentamidine,
respectively (Pohlig et al. 2008).
An additional Phase I study in which healthy
volunteers received pafuramidine 100mg BID for
14 days was conducted in the last quarter of 2007.
The study was designed to provide supportive safety
data for the registration of pafuramidine for sleeping
sickness and pneumocystis pneumonia. The pafura-
midine development programme was placed on clini-
cal hold by the US FDA to allow the investigation of
unexpected liver toxicity observed post-treatment
to this trial. Subsequently, 5 subjects of the same
healthy volunteer study developed renal insuﬃciency
approximately 8 weeks post- treatment that re-
quired medical intervention. Re-examination of the
Phase III sleeping sickness data identiﬁed 3 subjects
who had developed glomerulonephritis/nephropathy
post-pafuramidine treatment; 2 of these events may
retrospectively be considered possibly related to
pafuramidine. No patient in the pentamidine group
was reported to have renal disease. The clinical de-
velopment programme for pafuramidine was discon-
tinued at this time (Pohlig et al. 2008).
New Drugs
Eﬀorts to identify drug targets, and in high through-
put as well as live cell screening have been sub-
stantially increased and funded since the turn of the
century. A number of new drug targets have been
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identiﬁed and numerous compounds with promising
activity in preliminary tests identiﬁed. So far, drug
target validation and lead identiﬁcation and optim-
ization have proved to be diﬃcult, and consequently
there are currently only a very few molecules in pre-
clinical and only one in clinical development for
treatment of HAT. The most advanced new drug in
the pipeline is fexinidazole which belongs to the
nitroimidazole class of drugs which has previously
shown activity against trypanosomes. The molecule
was re-discovered during an extensive compound
mining eﬀort undertaken by the DNDi since 2005
to explore new and old nitroimidazoles as drug leads
against human African trypanosomiasis (HAT).
The substance proved to be orally active against
T. b. gambiense and T. b. rhodesiense in animal studies
and had an excellent safety proﬁle. Since it pen-
etrates the BBB it could be eﬀective in both stages
of sleeping sickness. In September 2009 the ﬁrst-
in-human Phase I study was initiated (DNDi, 2008b;
Anonymous, 2009).
Whatever the number and quality of compounds
emerging from the discovery process, their clinical
evaluation will remain critically diﬃcult. The case
of pafuramidine maleate has demonstrated that new
HAT drugs can be developed according to inter-
national guidances and under the scrutiny of a ﬁrst
tier regulatory agency (i.e. FDA). However, to con-
duct the necessary trials in rural, extremely resource-
limited and often insecure areas require substantial
eﬀort. Should the positive downwards trend in the
patient number (WHO, 2006) continue, the conduct
of Phase II and III trials will even become a more
diﬃcult and complex multi-site and multi-country
task. This will require substantial and continuous
funding, and it will be essential that where more than
one lead molecule is identiﬁed research is not pro-
gressed in a competitive manner. Instead, cooper-
ation and state-of-the-art trial design would be
demanded.
One of the major weaknesses of the clinical trials
conducted on HAT so far is the variety of deﬁnitions
for relapses, treatment failures and cure rates used.
This makes it virtually impossible to compare the
eﬃcacy results between trials and to perform meta-
analysis. TheWHO recently issued a reference docu-
ment for the conduct of clinical trials inHAT (WHO,
2007). It is strongly recommended that future clinical
trials on HAT should follow the deﬁnitions of this
guideline to facilitate collaboration in the evaluation
of new treatments and/or the comparison of data
obtained by diﬀerent groups. Standardization might
become particularly important in the light of the
previously mentioned further restrictions of HAT
drug trials due to decreasing patient numbers.
The ﬁrst large-scale clinical trial on HAT drugs,
the IMPAMEL I trial comparing one of the lengthy
standard schedules for treatment of second stage
disease with melarsoprol with an abridged 10-day
course, was initiated thirteen years ago (Burri et al.
2000). At this time therewere virtually no activities in
the ﬁeld of HAT drug development, and the interest
of the national sleeping sickness programmes in new
treatments was very limited due to the very long
tradition of complicated and toxic treatments and the
perceived lack of any prospect for better drugs in the
near future. The results of the IMPAMEL programme
weresomewhatfrustratingastheencephalopathic syn-
dromes could not been overcome, but it has pointed
the direction in the conduct of HAT trials - and in the
meantime we have travelled a long way. Right now,
we seem to be about leaving the dirt track and a better
engine to accelerate seems to have been ﬁtted to our
vehicle. After a diﬃcult experience with eﬂornithine
monotherapy, the nifurtimox-eﬂornithine combi-
nation treatment has a fair chance to supersede
melarsoprol as ﬁrst line treatment for second stage
T. b. gambiense disease. Travelling on a decent road
does not mean detours can be avoided as the example
of DB289 has shown. At this point the perseverance
from all those involved and continuous funding will
be required as we still will have to deal with a long and
winding road. Travelling ahead at the current pace
should eventually lead us to the promised destina-
tion, e.g. to modern, easier to administer drugs, or
even to drugs which may be simultaneously used
against ﬁrst and second stage disease and thus
eliminate the trouble of lumbar punctures.
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